Patents Represented by Attorney, Agent or Law Firm Li Su
  • Patent number: 7799825
    Abstract: The present invention relates to compounds of formula (I), and pharmaceutically acceptable salts and tautomers thereof. Compounds of the present invention are inhibitors of histone deacetylase (HDAC) and are useful for treating cellular proliferative diseases, including cancer. They are also useful for treating neurodegenerative diseases, mental retardation, 10 schizophrenia, inflammatory diseases, restenosis, immune disorders, diabetes, cardiovascular disorders and asthma.
    Type: Grant
    Filed: February 14, 2007
    Date of Patent: September 21, 2010
    Assignee: Istituto di Ricerche di Biologia Molecolare P. Angeletti SpA
    Inventors: Federica Ferrigno, Philip Jones, Ester Muraglia, Jesus Maria Ontoria Ontoria, Rita Scarpelli, Carsten Schultz-Fademrecht
  • Patent number: 7795304
    Abstract: The invention relates to hydroxamic acid derivatives having carbamate linkage with the structural formula that are inhibitors of histone deacetylase (HDAC), and are useful in the prevention and/or treatment of cellular proliferative diseases, for example cancer, autoimmune, allergic and inflammatory diseases, diseases of the central nervous systems (CNS) such as neurodegenerative diseases, and in the prevention and/or treatment of restenosis.
    Type: Grant
    Filed: August 22, 2005
    Date of Patent: September 14, 2010
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Sandro Belvedere, Christopher Laurence Hamblett, Thomas A. Miller, David J. Witter, Jiaming Yan
  • Patent number: 7772238
    Abstract: The present invention relates to a novel class of hydroxamic acid derivatives. The hydroxamic acid compounds can be used to treat cancer. The hydroxamic acid compounds can also inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention are also useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases.
    Type: Grant
    Filed: April 14, 2006
    Date of Patent: August 10, 2010
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jed Lee Hubbs, Sam Kattar, Joey Methot, Thomas Miller, Phieng Siliphaivanh, Matthew Stanton, Kevin Wilson, David J. Witter
  • Patent number: 7560546
    Abstract: The present invention relates to compounds that are capable of inhibiting, modulating and/or regulating signal transduction of both receptor-type and non-receptor type tyrosine kinases. The compounds of the instant invention possess a core structure that comprises a sulfonyl indole moiety. The present invention is also related to the pharmaceutically acceptable salts, hydrates and stereoisomers of these compounds.
    Type: Grant
    Filed: August 5, 2003
    Date of Patent: July 14, 2009
    Assignee: Merck & Co., Inc.
    Inventors: Christopher J. Dinsmore, Douglas C. Beshore, Jeffrey M. Bergman, Craig W. Lindsley
  • Patent number: 7538231
    Abstract: The present invention relates to compounds that are capable of inhibiting, modulating and/or regulating signal transduction of both receptor-type and non-receptor type tyrosine kinases. The compounds of the instant invention possess a core structure that comprises a substituted pyrrole moiety. The present invention is also related to the pharmaceutically acceptable salts, hydrates and stereoisomers of these compounds.
    Type: Grant
    Filed: July 20, 2004
    Date of Patent: May 26, 2009
    Assignee: Merck & Co, Inc.
    Inventor: Annette S. Kim
  • Patent number: 7507858
    Abstract: This invention relates to iminodiacetic acid and diamine hydroxamic acid derivatives, that are inhibitors of histone deacetylase (HDAC), and are useful in the prevention and/or treatment of cellular proliferative diseases, for example cancer, autoimmune, allergic and inflammatory diseases, diseases of the central nervous system (CNS) such as neurodegenerative diseases, and in the prevention and/or treatment of restenosis.
    Type: Grant
    Filed: July 15, 2005
    Date of Patent: March 24, 2009
    Assignee: Merck & Co., Inc.
    Inventors: Sandro Belvedere, Thomas A. Miller, David J. Witter
  • Patent number: 7504429
    Abstract: The present invention relates to compounds that are capable of inhibiting, modulating and/or regulating signal transduction of both receptor-type and non-receptor type tyrosine kinases. The compounds of the instant invention possess a core structure that comprises a substituted pyrrole moiety. The present invention is also related to the pharmaceutically acceptable salts, hydrates and stereoisomers of these compounds.
    Type: Grant
    Filed: July 20, 2004
    Date of Patent: March 17, 2009
    Assignee: Merck & Co., Inc.
    Inventors: Annette S. Kim, Xufang Zhang
  • Patent number: 7501435
    Abstract: The instant invention provides for compounds which comprise substituted triazoloquinazolinones that inhibit CHK1 activity. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting CHK1 activity by administering the compound to a patient in need of treatment of cancer.
    Type: Grant
    Filed: April 24, 2007
    Date of Patent: March 10, 2009
    Assignee: Merck & Co., Inc.
    Inventors: Kenneth L. Arrington, Edward J. Brnardic, Vadim Y. Dudkin, Mark E. Fraley, Shaei Y. Huang, Cheng Wang
  • Patent number: 7485649
    Abstract: The instant invention provides for compounds which comprise fused pyrazoles that inhibit CHK1 activity. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting CHK1 activity by administering the compound to a patient in need of treatment of cancer.
    Type: Grant
    Filed: January 5, 2006
    Date of Patent: February 3, 2009
    Assignee: Merck & Co., Inc.
    Inventors: Edward J. Brnardic, Mark E. Fraley, Robert M. Garbaccio
  • Patent number: 7371754
    Abstract: The present invention relates to compounds that are capable of inhibiting, modulating and/or regulating signal transduction of both receptor-type and non-receptor type tyrosine kinases. The compounds of the instant invention possess a core structure that comprises a benzazocine moiety. The present invention is also related to the pharmaceutically acceptable salts, hydrates and stereoisomers of these compounds.
    Type: Grant
    Filed: April 8, 2003
    Date of Patent: May 13, 2008
    Assignee: Merck & Co., Inc.
    Inventor: B. Wesley Trotter
  • Patent number: 7348431
    Abstract: The present invention relates to compounds that are capable of inhibiting, modulating and/or regulating signal transduction of both receptor-type and non-receptor type tyrosine kinases. The compounds of the instant invention possess a core structure that comprises a benzazocine moiety. The present invention is also related to the pharmaceutically acceptable salts, hydrates and stereoisomers of these compounds.
    Type: Grant
    Filed: April 8, 2003
    Date of Patent: March 25, 2008
    Assignee: Merck & Co., Inc.
    Inventor: Annette Kim
  • Patent number: 6806085
    Abstract: Recombinant DNA molecules are described which contain a DNA sequence encoding a protein with the biological activity of a 2-deoxyglucose-6-phosphate (2-DOG-6-P) phosphatase and being under the control of regulatory sequences of a promoter active in plants and transcription-termination and/or poyladenylation signals. Also, vectors and hosts are described which contain the recombinant DNA molecules according to the invention. Furthermore, processes for producing transformed plant cells and plants using the described recombinant DNA molecules and vectors are provided. The invention also describes transgenic plants, their harvest products and propagation material as well as plant cells and tissues containing the recombinant DNA molecules or vectors according to the invention or having been produced by the process according to the invention.
    Type: Grant
    Filed: April 25, 2000
    Date of Patent: October 19, 2004
    Assignee: IPK Gatersleben
    Inventors: Uwe Sonnewald, Marcus Ebneth
  • Patent number: 6790434
    Abstract: The invention relates to cosmetic compositions for topical application for counteracting UV radiation induced skin damage comprising as active substances a first component which comprises inactivated bacteria selected from the group consisting of the genus Bifidobacterium, Actinomycetaceae, Propionimycetaceae, Lactobacillaceae and Coryneform bacteria and a second component which comprises an extract of plant extracellular matrix. Preferably, the plant extracellular matrix is selected from the group consisting of glycoproteins, carbohydrate polymers and arabinogalactan proteins. Processes for using the cosmetic compositions are also described.
    Type: Grant
    Filed: November 5, 2001
    Date of Patent: September 14, 2004
    Assignee: Chemisches Laboratorium Dr. Kurt Richter GmbH
    Inventors: Stefan Borchert, Rolf-Dieter Petersen
  • Patent number: 6692965
    Abstract: The invention is directed to reliable and efficient detection of mRNAs as well as other RNAs in living cells and its use to identify and, if desired, separate cells based on their desired characteristics. Such methods greatly simplify and reduce the time necessary to carry out previously-known procedures, and offers new approaches as well, such as selecting cells that generate a particular protein or antisense oligonucleotide, generating cell lines that express multiple proteins, generating cell lines with knock-out of one or more protein, and others.
    Type: Grant
    Filed: November 22, 2000
    Date of Patent: February 17, 2004
    Assignee: Chromocell Corporation
    Inventors: Kambiz Shekdar, Gunter Blobel
  • Patent number: 6348315
    Abstract: The present invention relates to methods for identifying nucleic acid molecules encoding (poly)peptides that interact with target molecules. The method of the present invention is particularly characterized by an in vitro translation step under conditions that allow formation of polysomes in the presence of antisense oligonucleotides complementary to the tag-coding sequence of ssrA-RNA. The present invention further relates to kits that are useful for carrying out the method of the invention.
    Type: Grant
    Filed: October 22, 1999
    Date of Patent: February 19, 2002
    Assignee: University of Zürich, Assignee for Josef Hanes
    Inventors: Andreas Plückthun, Jozef Hanes, Lutz Jermutus
  • Patent number: 6255561
    Abstract: Nucleic acid molecules are described, which encode debranching enzymes from maize, as well as transgenic plant cells and plants in which an amylopectin with modified properties is synthesized due to the expression of a debranching enzyme from maize or due to the inhibition of such an endogeneous debranching enzyme activity.
    Type: Grant
    Filed: September 4, 1998
    Date of Patent: July 3, 2001
    Assignee: PlantTec Biotechnologie GmbH
    Inventors: Jens Kossman, Lothar Willmitzer, Michael Emmermann
  • Patent number: 6255563
    Abstract: Nucleic acid molecules are described, which encode debranching enzymes from potato, as well as transgenic plant cells and plants in which an amylopectin with modified properties is synthesized due to the expression of a debranching enzyme from potato or due to the inhibition of such an endogeneous debranching enzyme activity.
    Type: Grant
    Filed: November 5, 1998
    Date of Patent: July 3, 2001
    Assignee: PlantTec Biotechnologie GmbH
    Inventors: Michael Emmermann, Jens Kossmann
  • Patent number: 6211436
    Abstract: Nucleic acid molecules encoding enzymes which participate in the starch synthesis in plants are described. These enzymes are a novel isotype of starch synthase. Furthermore, the invention relates to vectors and host cells which were transformed with the described nucleic acid molecules, in particular to transformed plant cells and to plants which may be regenerated therefrom and which exhibit an increased or reduced activity of the described proteins.
    Type: Grant
    Filed: July 15, 1998
    Date of Patent: April 3, 2001
    Assignee: Planttec Biotechnologie GmbH
    Inventors: Jens Kossmann, Claus Frohberg